Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

GLP-1s have dominated discussions in 2024 among those exploring weight-loss treatments. However, Zealand Pharma A/S (CPH: ...

After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

Air bubble formation from pressure changes causes the pump to deliver about 0.6 extra units on ascent and about 0.5 less on ...

Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical ...

Amid the stock market frenzy surrounding weight-loss medicines, one Belgian biotech company is rewarding investors by ...

Type 1 Diabetes Market Set To Eyewitness Substantial Growth By 2024-2031: Sanofi, Wockhardt Ltd., Ypsomed AG, Novartis Type 1 Diabetes Market is expected to reach USD 24.36 Bn by 2031, exhibiting a ...

The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...